PHVS logo

Pharvaris N.V. (PHVS)

$32.44

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PHVS

Market cap

$2.26B

EPS

-3.49

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

-2.475523

Price on PHVS

Previous close

$33.36

Today's open

$33.19

Day's range

$32.44 - $34.46

52 week range

$23.01 - $43.25

Profile about PHVS

CEO

Berndt Modig

Employees

129

Headquarters

Leiden,

Exchange

Nasdaq Global Select

Shares outstanding

69666453

Issue type

Common Stock

PHVS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on PHVS

Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?

The mean of analysts' price targets for Pharvaris (PHVS) points to a 79.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

news source

Zacks Investment Research • Nov 16, 2026

news preview

Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update

ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the third quarter ending on September 30, 2026, and provided a business update.

news source

GlobeNewsWire • Nov 12, 2026

news preview

Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the oral and poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16, 2026, in Phoenix, Arizona. The presentations include late-breaking results from the Phase 3 CHAPTER-3 study evaluating investigational oral deucrictibant extended-release (XR) tablet for prophylaxis of HAE attacks to be presented in the Distinguished Industry and Late-breaking Oral Abstracts sessions on Saturday, November 14 from 4:30 – 6:00 p.m. MST, as well as final long-term results from the prophylaxis Phase 2 open-label extension, additional analyses of the pivotal Phase 3 on-demand treatment study, clinical pharmacology data supporting the potential combined use of the XR and immediate-release (IR) formulations, a comprehensive assessment of deucrictibant's cardiovascular safety across the development program, and the real-world economic burden of HAE.

news source

GlobeNewsWire • Nov 12, 2026

news preview

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14

news source

GlobeNewsWire • Oct 29, 2026

news preview

Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

Bank of America Securities on Friday upgraded Pharvaris N.V. (NASDAQ:PHVS), citing an attractive entry point with clinical risk largely removed.

news source

Benzinga • Oct 23, 2026

news preview

Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global, randomized, double-blind, placebo-controlled crossover study evaluating oral deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of HAE attacks in adolescents and adults have been published in  The Lancet (Journal Impact Factor: 109.0).

news source

GlobeNewsWire • Oct 8, 2026

news preview

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options

news source

GlobeNewsWire • Oct 5, 2026

news preview

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 15, 2026

news preview

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

news source

Zacks Investment Research • Sep 15, 2026

news preview

Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win

Pharvaris N.V. maintains a 'Strong Buy' rating following pivotal phase 3 wins for both on-demand and prophylactic HAE therapies. PHVS achieved rapid symptom relief in RAPIDe-3 [median 1.28 hours, p

news source

Seeking Alpha • Sep 9, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Pharvaris N.V.

Open an M1 investment account to buy and sell Pharvaris N.V. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PHVS on M1